New Pill for MS Shows Promise in Clinical Trial

HealthDay News — A new oral medication for the treatment of multiple sclerosis MS shows promise in slowing disease progression, limiting brain atrophy and reducing MS relapses, a recently completed two-year clinical trial demonstrates.The findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.The study found that to date, the new drug appears to be both safe and well-tolerated. If the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.

via New Pill for MS Shows Promise in Clinical Trial.

Share

Merck says US rejects its MS drug

(AFP) – German pharmaceutical group Merck KgaA said Wednesday that the US Food and Drug Administration (FDA) has refused to approve use of its multiple sclerosis treatment Cladribine.

The FDA declined to approve the drug "in its present form" and asked Merck to "provide an improved understanding of the safety risks and the overall benefit-risk profile," either through additional analyses or studies.

via Merck says US rejects its MS drug – Yahoo! News.

Share